Wednesday, June 10, 2026
🇺🇸 FDA

pharma · Inflammatory Bowel Disease (IBD) · Melanoma · IRON

Disc Medicine

Disc Medicine drug portfolio — 200 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.

Website Investor relations
321 Arsenal St., Suite 101, Watertown, Massachusetts 02472-5710, US HQ
165 Employees
Public company Type
IRON · NYSE Ticker
Company details
Status
Public
HQ
321 Arsenal St., Suite 101, Watertown, Massachusetts 02472-5710, US
Employees
165
Programs
308
Drugs
442
Patents
706
Official website ↗ All projects Drug pipeline Patents News & analysis
Intelligence · Drug Pipeline

Disc Medicine pipeline

Portfolio lens on 200 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.

Disc Medicine drug portfolio — 200 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.

Drug portfolio

200 compounds

  1. 99mtc-hpark2

    Development asset linked to Disc Medicine in public FDA and regional records.

  2. abacavir

    Antiinfectives for systemic use (J05)

    US regulatory status: approved.

  3. abacavir sulfate

    US regulatory status: approved. Molecular target: Human immunodeficiency virus type 1 reverse transcriptase.

    Target
    Human immunodeficiency virus type 1 reverse transcriptase
    Mechanism
    Human immunodeficiency virus type 1 reverse transcriptase inhibitor

  5. abobotulinumtoxina

    US regulatory status: approved. Molecular target: Synaptosomal-associated protein 25.

    Target
    Synaptosomal-associated protein 25
    Mechanism
    Synaptosomal-associated protein 25 inhibitor

  6. acetaminophen

    US regulatory status: approved. Molecular target: Fatty-acid amide hydrolase 1.

    Target
    Fatty-acid amide hydrolase 1
    Mechanism
    Cyclooxygenase inhibitor

  7. adalimumab

    Antineoplastic and immunomodulating agents (L04)

    US regulatory status: approved. Molecular target: Tumor necrosis factor.

    Target
    Tumor necrosis factor
    Mechanism
    TNF-alpha inhibitor

  8. administered

    Development asset linked to Disc Medicine in public FDA and regional records.

  9. administration

    Development asset linked to Disc Medicine in public FDA and regional records.

  10. adoptive

    Development asset linked to Disc Medicine in public FDA and regional records.

  11. agomelatine

    Nervous system (N06)

    Nervous system (N06) compound in Disc Medicine's portfolio. Molecular target: Melatonin receptor.

    Target
    Melatonin receptor
    Mechanism
    Melatonin receptor agonist

  12. aldesleukin

    US regulatory status: approved. Molecular target: Interleukin-2 receptor.

    Target
    Interleukin-2 receptor
    Mechanism
    Interleukin-2 receptor agonist

  13. alectinib

    Antineoplastic and immunomodulating agents (L01)

    Antineoplastic and immunomodulating agents (L01) compound in Disc Medicine's portfolio. Mechanism: EML4-ALK.

    Mechanism
    EML4-ALK

  14. alglucosidase alfa

    Alimentary tract and metabolism (A16)

    US regulatory status: approved. Molecular target: Starch.

    Target
    Starch
    Mechanism
    Starch hydrolytic enzyme

  15. alitretinoin

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Retinoid receptor.

    Target
    Retinoid receptor
    Mechanism
    Retinoid receptor agonist

  16. alteplase

    US regulatory status: approved. Molecular target: Tissue-type plasminogen activator.

    Target
    Tissue-type plasminogen activator
    Mechanism
    Tissue-type plasminogen activator exogenous protein

  17. alzheimer

    Development asset linked to Disc Medicine in public FDA and regional records.

  18. amisulpride

    US regulatory status: approved. Molecular target: Dopamine receptors; D2 & D3.

    Target
    Dopamine receptors; D2 & D3
    Mechanism
    Serotonin (5-HT) receptor antagonist

  19. amitriptyline

    Development asset linked to Disc Medicine in public FDA and regional records. Mechanism: Serotonin transporter inhibitor.

    Mechanism
    Serotonin transporter inhibitor

  20. amoxicillin

    US regulatory status: approved. Molecular target: Bacterial penicillin-binding protein.

    Target
    Bacterial penicillin-binding protein
    Mechanism
    Bacterial penicillin-binding protein inhibitor

  21. amphotericin b

    US regulatory status: approved. Molecular target: Ergosterol.

    Target
    Ergosterol
    Mechanism
    Ergosterol sequestering agent

  22. anakinra

    Antineoplastic and immunomodulating agents (L04)

    US regulatory status: approved. Molecular target: Interleukin-1 receptor type 1.

    Target
    Interleukin-1 receptor type 1
    Mechanism
    Interleukin-1 receptor antagonist

  23. anesthesia

    Development asset linked to Disc Medicine in public FDA and regional records.

  24. angiotensin ii acetate

    US regulatory status: approved. Molecular target: Type-1 angiotensin II receptor.

    Target
    Type-1 angiotensin II receptor
    Mechanism
    Type-1 angiotensin II receptor agonist

  25. anifrolumab

    Antineoplastic and immunomodulating agents (L04)

    Antineoplastic and immunomodulating agents (L04) compound in Disc Medicine's portfolio. Molecular target: Interferon alpha/beta receptor 1.

    Target
    Interferon alpha/beta receptor 1
    Mechanism
    Interferon-alpha/beta receptor alpha chain antagonist

  26. anti-

    Development asset linked to Disc Medicine in public FDA and regional records.

  27. anti-melanoma mab fragments

    Various (V09)

    Various (V09) compound in Disc Medicine's portfolio. Mechanism: Diagnostic agent.

    Mechanism
    Diagnostic agent

  28. antibody

    Development asset linked to Disc Medicine in public FDA and regional records.

  29. apalutamide

    Antineoplastic and immunomodulating agents (L02)

    US regulatory status: approved. Molecular target: Androgen receptor.

    Target
    Androgen receptor
    Mechanism
    Androgen Receptor antagonist

  30. aripiprazole

    Nervous system (N05)

    US regulatory status: approved. Molecular target: D(2) dopamine receptor.

    Target
    D(2) dopamine receptor
    Mechanism
    Serotonin 2a (5-HT2a) receptor antagonist

  31. arthroplasty

    Development asset linked to Disc Medicine in public FDA and regional records.

  32. asenapine

    Nervous system (N05)

    US regulatory status: approved. Mechanism: Serotonin 2a (5-HT2a) receptor antagonist.

    Mechanism
    Serotonin 2a (5-HT2a) receptor antagonist

  33. atazanavir sulfate

    Antiinfectives for systemic use (J05)

    US regulatory status: approved. Molecular target: Human immunodeficiency virus type 1 protease.

    Target
    Human immunodeficiency virus type 1 protease
    Mechanism
    Human immunodeficiency virus type 1 protease inhibitor

  34. atezolizumab

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Programmed cell death 1 ligand 1.

    Target
    Programmed cell death 1 ligand 1
    Mechanism
    Programmed cell death 1 ligand 1 inhibitor

  35. atomoxetine

    Development asset linked to Disc Medicine in public FDA and regional records. Mechanism: Norepinephrine transporter inhibitor.

    Mechanism
    Norepinephrine transporter inhibitor

  36. atorvastatin

    Development asset linked to Disc Medicine in public FDA and regional records. Mechanism: HMG-CoA reductase inhibitor.

    Mechanism
    HMG-CoA reductase inhibitor

  37. atropine

    Sensory organs (S01)

    US regulatory status: approved. Molecular target: Muscarinic acetylcholine receptor M1.

    Target
    Muscarinic acetylcholine receptor M1
    Mechanism
    Muscarinic acetylcholine receptor M1 antagonist

  38. atropine sulfate

    Sensory organs (S01)

    US regulatory status: approved. Molecular target: Muscarinic acetylcholine receptor M1.

    Target
    Muscarinic acetylcholine receptor M1
    Mechanism
    Muscarinic acetylcholine receptor M3 antagonist

  39. autologous

    Development asset linked to Disc Medicine in public FDA and regional records.

  41. avalglucosidase alfa

    Alimentary tract and metabolism (A16)

    Alimentary tract and metabolism (A16) compound in Disc Medicine's portfolio. Molecular target: Glycogen.

    Target
    Glycogen
    Mechanism
    Glycogen hydrolytic enzyme

  42. avelumab

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Programmed cell death 1 ligand 1.

    Target
    Programmed cell death 1 ligand 1
    Mechanism
    Programmed cell death 1 ligand 1 other

  43. axicabtagene ciloleucel

    Antineoplastic and immunomodulating agents (L01)

    Antineoplastic and immunomodulating agents (L01) compound in Disc Medicine's portfolio. Molecular target: B-lymphocyte antigen CD19.

    Target
    B-lymphocyte antigen CD19
    Mechanism
    B-lymphocyte antigen CD19 binding agent

  44. azathioprine

    Antineoplastic and immunomodulating agents (L04)

    US regulatory status: approved. Molecular target: Amidophosphoribosyltransferase.

    Target
    Amidophosphoribosyltransferase
    Mechanism
    Amidophosphoribosyltransferase inhibitor

  45. azithromycin

    US regulatory status: approved. Molecular target: Bacterial 70S ribosome.

    Target
    Bacterial 70S ribosome
    Mechanism
    Bacterial 70S ribosome inhibitor

  46. baloxavir

    Development asset linked to Disc Medicine in public FDA and regional records. Molecular target: Polymerase acidic protein.

    Target
    Polymerase acidic protein
    Mechanism
    Polymerase acidic protein inhibitor

  47. baloxavir marboxil

    US regulatory status: approved. Molecular target: Polymerase acidic protein.

    Target
    Polymerase acidic protein
    Mechanism
    Polymerase acidic protein inhibitor

  48. baricitinib

    Antineoplastic and immunomodulating agents (L04)

    US regulatory status: approved. Molecular target: Tyrosine-protein kinase JAK1.

    Target
    Tyrosine-protein kinase JAK1
    Mechanism
    Tyrosine-protein kinase JAK2 inhibitor

  49. basiliximab

    Antineoplastic and immunomodulating agents (L04)

    US regulatory status: approved. Molecular target: Interleukin-2 receptor.

    Target
    Interleukin-2 receptor
    Mechanism
    Interleukin-2 receptor inhibitor

  50. beclometasone

    Respiratory system (R03)

    Respiratory system (R03) compound in Disc Medicine's portfolio.

  51. betamethasone valerate

    US regulatory status: approved. Molecular target: Glucocorticoid receptor.

    Target
    Glucocorticoid receptor
    Mechanism
    Glucocorticoid receptor agonist

  52. bevacizumab

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Vascular endothelial growth factor A, long form.

    Target
    Vascular endothelial growth factor A, long form
    Mechanism
    Vascular endothelial growth factor A inhibitor

  53. binimetinib

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Dual specificity mitogen-activated protein kinase kinase 1.

    Target
    Dual specificity mitogen-activated protein kinase kinase 1
    Mechanism
    Dual specificity mitogen-activated protein kinase kinase 1 inhibitor

  54. bortezomib

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: 26S proteasome.

    Target
    26S proteasome
    Mechanism
    26S proteosome inhibitor

  55. bosutinib

    Antineoplastic and immunomodulating agents (L01)

    Antineoplastic and immunomodulating agents (L01) compound in Disc Medicine's portfolio. Molecular target: Tyrosine-protein kinase ABL1.

    Target
    Tyrosine-protein kinase ABL1
    Mechanism
    Tyrosine-protein kinase ABL inhibitor

  56. botulinum toxin type a

    Musculo-skeletal system (M03)

    Musculo-skeletal system (M03) compound in Disc Medicine's portfolio. Molecular target: Synaptosomal-associated protein 25.

    Target
    Synaptosomal-associated protein 25
    Mechanism
    Synaptosomal nerve-associated protein 25 (SNAP-25) hydrolytic enzyme

  57. brentuximab

    Development asset linked to Disc Medicine in public FDA and regional records.

  58. brexpiprazole

    Nervous system (N05)

    US regulatory status: approved. Molecular target: D(2) dopamine receptor.

    Target
    D(2) dopamine receptor
    Mechanism
    Serotonin 2a (5-HT2a) receptor antagonist

  59. budesonide

    Alimentary tract and metabolism (A07)

    US regulatory status: approved. Molecular target: Glucocorticoid receptor.

    Target
    Glucocorticoid receptor
    Mechanism
    Glucocorticoid receptor agonist

  60. buprenorphine

    Nervous system (N07)

    US regulatory status: approved. Molecular target: Kappa-type opioid receptor.

    Target
    Kappa-type opioid receptor
    Mechanism
    Kappa opioid receptor agonist

  61. buprenorphine hydrochloride

    US regulatory status: approved. Molecular target: Kappa-type opioid receptor.

    Target
    Kappa-type opioid receptor
    Mechanism
    Mu opioid receptor agonist

  62. bupropion

    Development asset linked to Disc Medicine in public FDA and regional records. Mechanism: Dopamine transporter inhibitor.

    Mechanism
    Dopamine transporter inhibitor

  63. c1 inhibitor (human)

    Blood and blood forming organs (B06)

    Blood and blood forming organs (B06) compound in Disc Medicine's portfolio. Molecular target: Coagulation factor XI.

    Target
    Coagulation factor XI
    Mechanism
    Coagulation factor XI inhibitor

  64. cabazitaxel

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Tubulin.

    Target
    Tubulin
    Mechanism
    Tubulin inhibitor

  65. cabozantinib

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Mechanism: Hepatocyte growth factor receptor inhibitor.

    Mechanism
    Hepatocyte growth factor receptor inhibitor

  66. calcium

    US regulatory status: approved.

  67. calcium chloride

    US regulatory status: approved. Mechanism: Dihydrofolate reductase inhibitor.

    Mechanism
    Dihydrofolate reductase inhibitor

  68. canagliflozin

    Alimentary tract and metabolism (A10)

    US regulatory status: approved. Molecular target: Sodium/glucose cotransporter 2.

    Target
    Sodium/glucose cotransporter 2
    Mechanism
    Sodium/glucose cotransporter 2 inhibitor

  69. cannabidiol

    Nervous system (N03)

    US regulatory status: approved. Molecular target: Cannabinoid receptor 1.

    Target
    Cannabinoid receptor 1
    Mechanism
    Cannabinoid CB1 receptor negative allosteric modulator

  70. capecitabine

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: DNA.

    Target
    DNA
    Mechanism
    Thymidylate synthase inhibitor

  71. capsaicin

    Nervous system (N01)

    US regulatory status: approved. Molecular target: Transient receptor potential cation channel subfamily V member 1.

    Target
    Transient receptor potential cation channel subfamily V member 1
    Mechanism
    Vanilloid receptor opener

  72. capsule

    Development asset linked to Disc Medicine in public FDA and regional records.

  73. capsules

    Development asset linked to Disc Medicine in public FDA and regional records.

  74. carbamazepine

    US regulatory status: approved. Molecular target: Sodium channel alpha subunit.

    Target
    Sodium channel alpha subunit
    Mechanism
    Sodium channel alpha subunit blocker

  75. carboplatin

    US regulatory status: approved. Molecular target: DNA.

    Target
    DNA
    Mechanism
    DNA inhibitor

  76. carfilzomib

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: 26S proteasome.

    Target
    26S proteasome
    Mechanism
    26S proteosome inhibitor

  77. cariprazine

    Nervous system (N05)

    Nervous system (N05) compound in Disc Medicine's portfolio. Mechanism: Dopamine D3 receptor modulator.

    Mechanism
    Dopamine D3 receptor modulator

  78. carisoprodol

    US regulatory status: approved. Mechanism: Unknown.

    Mechanism
    Unknown

  79. cart

    Development asset linked to Disc Medicine in public FDA and regional records.

  80. cefiderocol sulfate tosylate

    US regulatory status: approved. Molecular target: Bacterial penicillin-binding protein.

    Target
    Bacterial penicillin-binding protein
    Mechanism
    Bacterial penicillin-binding protein inhibitor

  81. ceftriaxone sodium

    US regulatory status: approved. Molecular target: Bacterial penicillin-binding protein.

    Target
    Bacterial penicillin-binding protein
    Mechanism
    Bacterial penicillin-binding protein inhibitor

  82. cells

    Development asset linked to Disc Medicine in public FDA and regional records.

  83. cemiplimab

    Antineoplastic and immunomodulating agents (L01)

    Antineoplastic and immunomodulating agents (L01) compound in Disc Medicine's portfolio. Molecular target: Programmed cell death protein 1.

    Target
    Programmed cell death protein 1
    Mechanism
    Programmed cell death protein 1 inhibitor

  84. certolizumab pegol

    Antineoplastic and immunomodulating agents (L04)

    US regulatory status: approved. Molecular target: Tumor necrosis factor.

    Target
    Tumor necrosis factor
    Mechanism
    TNF-alpha inhibitor

  85. cetuximab

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Epidermal growth factor receptor.

    Target
    Epidermal growth factor receptor
    Mechanism
    Epidermal growth factor receptor erbB1 inhibitor

  86. chemoradiation

    Development asset linked to Disc Medicine in public FDA and regional records.

  87. chemotherapy

    Development asset linked to Disc Medicine in public FDA and regional records.

  88. chloride

    Development asset linked to Disc Medicine in public FDA and regional records.

  89. chlorpromazine

    US regulatory status: approved. Molecular target: D2-like dopamine receptor.

    Target
    D2-like dopamine receptor
    Mechanism
    D2-like dopamine receptor antagonist

  90. chymopapain

    US regulatory status: approved. Molecular target: Polypeptides.

    Target
    Polypeptides
    Mechanism
    Polypeptides proteolytic enzyme

  91. ciclosporin

    Sensory organs (S01)

    Sensory organs (S01) compound in Disc Medicine's portfolio. Molecular target: Peptidyl-prolyl cis-trans isomerase A.

    Target
    Peptidyl-prolyl cis-trans isomerase A
    Mechanism
    Cyclophilin A modulator

  92. cipaglucosidase alfa

    Alimentary tract and metabolism (A16)

    Alimentary tract and metabolism (A16) compound in Disc Medicine's portfolio. Molecular target: Glycogen.

    Target
    Glycogen
    Mechanism
    Glycogen hydrolytic enzyme

  93. cisplatin

    US regulatory status: approved. Molecular target: DNA.

    Target
    DNA
    Mechanism
    DNA inhibitor

  94. citalopram

    Development asset linked to Disc Medicine in public FDA and regional records. Mechanism: Serotonin transporter inhibitor.

    Mechanism
    Serotonin transporter inhibitor

  95. clarithromycin

    US regulatory status: approved. Molecular target: Bacterial 70S ribosome.

    Target
    Bacterial 70S ribosome
    Mechanism
    Bacterial 70S ribosome inhibitor

  96. clobazam

    US regulatory status: approved. Molecular target: GABA-A receptor; anion channel.

    Target
    GABA-A receptor; anion channel
    Mechanism
    GABA-A receptor; anion channel positive allosteric modulator

  97. clomipramine

    Development asset linked to Disc Medicine in public FDA and regional records. Mechanism: Serotonin transporter inhibitor.

    Mechanism
    Serotonin transporter inhibitor

  98. clopidogrel

    Blood and blood forming organs (B01)

    Blood and blood forming organs (B01) compound in Disc Medicine's portfolio. Mechanism: Purinergic receptor P2Y12 antagonist.

    Mechanism
    Purinergic receptor P2Y12 antagonist

  99. clopidogrel bisulfate

    US regulatory status: approved. Molecular target: P2Y purinoceptor 12.

    Target
    P2Y purinoceptor 12
    Mechanism
    Purinergic receptor P2Y12 antagonist

  101. clozapine

    US regulatory status: approved. Molecular target: D(2) dopamine receptor.

    Target
    D(2) dopamine receptor
    Mechanism
    Serotonin 2a (5-HT2a) receptor antagonist

  102. cobicistat

    Various (V03)

    US regulatory status: approved. Molecular target: Cytochrome P450 3A.

    Target
    Cytochrome P450 3A
    Mechanism
    Cytochrome P450 3A inhibitor

  103. colchicine

    Musculo-skeletal system (M04)

    US regulatory status: approved. Molecular target: Tubulin.

    Target
    Tubulin
    Mechanism
    Tubulin inhibitor

  104. combination

    Development asset linked to Disc Medicine in public FDA and regional records.

  106. control

    Development asset linked to Disc Medicine in public FDA and regional records.

  107. corticosteroid

    Development asset linked to Disc Medicine in public FDA and regional records.

  108. corticosteroids

    Development asset linked to Disc Medicine in public FDA and regional records.

  109. corticotropin

    US regulatory status: approved. Molecular target: Adrenocorticotropic hormone receptor.

    Target
    Adrenocorticotropic hormone receptor
    Mechanism
    Melanocortin receptor 2 agonist

  110. cortisone

    Development asset linked to Disc Medicine in public FDA and regional records.

  111. crizotinib

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: ALK tyrosine kinase receptor.

    Target
    ALK tyrosine kinase receptor
    Mechanism
    Hepatocyte growth factor receptor inhibitor

  112. cyclophosphamide

    US regulatory status: approved. Molecular target: DNA.

    Target
    DNA
    Mechanism
    DNA inhibitor

  113. dabrafenib

    Antineoplastic and immunomodulating agents (L01)

    Antineoplastic and immunomodulating agents (L01) compound in Disc Medicine's portfolio. Mechanism: Serine/threonine-protein kinase B-raf inhibitor.

    Mechanism
    Serine/threonine-protein kinase B-raf inhibitor

  114. dapagliflozin

    Alimentary tract and metabolism (A10)

    US regulatory status: approved. Molecular target: Sodium/glucose cotransporter 2.

    Target
    Sodium/glucose cotransporter 2
    Mechanism
    Sodium/glucose cotransporter 2 inhibitor

  115. daratumumab

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1.

    Target
    ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1
    Mechanism
    Lymphocyte differentiation antigen CD38 inhibitor

  116. darbepoetin alfa

    Blood and blood forming organs (B03)

    US regulatory status: approved. Molecular target: Erythropoietin receptor.

    Target
    Erythropoietin receptor
    Mechanism
    Erythropoietin receptor agonist

  117. darolutamide

    Antineoplastic and immunomodulating agents (L02)

    US regulatory status: approved. Molecular target: Androgen receptor.

    Target
    Androgen receptor
    Mechanism
    Androgen Receptor antagonist

  118. dasatinib

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Bcr/Abl fusion protein.

    Target
    Bcr/Abl fusion protein
    Mechanism
    SRC inhibitor

  119. deferoxamine

    Development asset linked to Disc Medicine in public FDA and regional records.

  120. dendritic

    Development asset linked to Disc Medicine in public FDA and regional records.

  121. denosumab

    Musculo-skeletal system (M05)

    US regulatory status: approved. Molecular target: Tumor necrosis factor ligand superfamily member 11.

    Target
    Tumor necrosis factor ligand superfamily member 11
    Mechanism
    Tumor necrosis factor ligand superfamily member 11 inhibitor

  122. desonide

    US regulatory status: approved. Molecular target: Glucocorticoid receptor.

    Target
    Glucocorticoid receptor
    Mechanism
    Glucocorticoid receptor agonist

  123. desvenlafaxine

    US regulatory status: approved. Molecular target: Sodium-dependent noradrenaline transporter.

    Target
    Sodium-dependent noradrenaline transporter
    Mechanism
    Norepinephrine transporter inhibitor

  124. desvenlafaxine fumarate

    US regulatory status: approved. Molecular target: Sodium-dependent noradrenaline transporter.

    Target
    Sodium-dependent noradrenaline transporter
    Mechanism
    Norepinephrine transporter inhibitor

  125. desvenlafaxine succinate

    US regulatory status: approved. Molecular target: Sodium-dependent noradrenaline transporter.

    Target
    Sodium-dependent noradrenaline transporter
    Mechanism
    Serotonin transporter inhibitor

  126. dexamethasone phosphate

    Systemic hormonal preparations (H02)

    Systemic hormonal preparations (H02) compound in Disc Medicine's portfolio.

  127. dexamethasone sodium phosphate

    US regulatory status: approved. Molecular target: Glucocorticoid receptor.

    Target
    Glucocorticoid receptor
    Mechanism
    Glucocorticoid receptor agonist

  128. diethylpropion hydrochloride

    US regulatory status: approved. Molecular target: Sodium-dependent dopamine transporter.

    Target
    Sodium-dependent dopamine transporter
    Mechanism
    Norepinephrine transporter inhibitor

  129. digoxin

    US regulatory status: approved. Molecular target: Sodium/potassium-transporting ATPase.

    Target
    Sodium/potassium-transporting ATPase
    Mechanism
    Sodium/potassium-transporting ATPase inhibitor

  130. diltiazem

    Development asset linked to Disc Medicine in public FDA and regional records. Mechanism: Voltage-gated L-type calcium channel blocker.

    Mechanism
    Voltage-gated L-type calcium channel blocker

  131. dipyridamole

    US regulatory status: approved. Molecular target: 3',5'-cyclic phosphodiesterase.

    Target
    3',5'-cyclic phosphodiesterase
    Mechanism
    3',5'-cyclic phosphodiesterase inhibitor

  132. docetaxel

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Tubulin.

    Target
    Tubulin
    Mechanism
    Tubulin inhibitor

  133. dolutegravir

    Antiinfectives for systemic use (J05)

    US regulatory status: approved.

  134. doravirine

    Antiinfectives for systemic use (J05)

    US regulatory status: approved. Molecular target: Human immunodeficiency virus type 1 reverse transcriptase.

    Target
    Human immunodeficiency virus type 1 reverse transcriptase
    Mechanism
    Human immunodeficiency virus type 1 reverse transcriptase negative allosteric modulator

  135. dose

    Development asset linked to Disc Medicine in public FDA and regional records.

  136. dose-escalation

    Development asset linked to Disc Medicine in public FDA and regional records.

  137. dosulepin

    Development asset linked to Disc Medicine in public FDA and regional records. Molecular target: Sodium-dependent noradrenaline transporter.

    Target
    Sodium-dependent noradrenaline transporter
    Mechanism
    Norepinephrine transporter inhibitor

  138. dronabinol

    US regulatory status: approved. Molecular target: Cannabinoid receptor 1.

    Target
    Cannabinoid receptor 1
    Mechanism
    Cannabinoid CB1 receptor agonist

  139. duloxetine

    Nervous system (N06)

    Nervous system (N06) compound in Disc Medicine's portfolio. Mechanism: Serotonin transporter inhibitor.

    Mechanism
    Serotonin transporter inhibitor

  140. duloxetine hydrochloride

    US regulatory status: approved. Molecular target: Sodium-dependent noradrenaline transporter.

    Target
    Sodium-dependent noradrenaline transporter
    Mechanism
    Norepinephrine transporter inhibitor

  141. durvalumab

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Programmed cell death 1 ligand 1.

    Target
    Programmed cell death 1 ligand 1
    Mechanism
    Programmed cell death 1 ligand 1 inhibitor

  142. edoxaban

    Blood and blood forming organs (B01)

    US regulatory status: approved. Mechanism: Coagulation factor X inhibitor.

    Mechanism
    Coagulation factor X inhibitor

  143. elotuzumab

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: SLAM family member 7.

    Target
    SLAM family member 7
    Mechanism
    SLAM family member 7 inhibitor

  144. emicizumab

    Blood and blood forming organs (B02)

    US regulatory status: approved. Molecular target: Coagulation factor IX and X.

    Target
    Coagulation factor IX and X
    Mechanism
    Coagulation factor IX and X other

  145. empagliflozin

    Alimentary tract and metabolism (A10)

    US regulatory status: approved. Molecular target: Sodium/glucose cotransporter 2.

    Target
    Sodium/glucose cotransporter 2
    Mechanism
    Sodium/glucose cotransporter 2 inhibitor

  146. emtricitabine

    Antiinfectives for systemic use (J05)

    US regulatory status: approved. Molecular target: Human immunodeficiency virus type 1 reverse transcriptase.

    Target
    Human immunodeficiency virus type 1 reverse transcriptase
    Mechanism
    Human immunodeficiency virus type 1 reverse transcriptase inhibitor

  148. encorafenib

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Serine/threonine-protein kinase B-raf.

    Target
    Serine/threonine-protein kinase B-raf
    Mechanism
    Serine/threonine-protein kinase B-raf inhibitor

  149. endocrine

    Development asset linked to Disc Medicine in public FDA and regional records.

  150. enfortumab vedotin

    Antineoplastic and immunomodulating agents (L01)

    Antineoplastic and immunomodulating agents (L01) compound in Disc Medicine's portfolio. Molecular target: Nectin-4.

    Target
    Nectin-4
    Mechanism
    Tubulin inhibitor

  151. enoxaparin sodium

    Blood and blood forming organs (B01)

    US regulatory status: approved. Molecular target: Antithrombin-III.

    Target
    Antithrombin-III
    Mechanism
    Antithrombin-III activator

  152. enzalutamide

    Antineoplastic and immunomodulating agents (L02)

    US regulatory status: approved. Molecular target: Androgen receptor.

    Target
    Androgen receptor
    Mechanism
    Androgen Receptor antagonist

  153. epinephrine

    Cardiovascular system (C01)

    US regulatory status: approved. Molecular target: Adrenergic receptor.

    Target
    Adrenergic receptor
    Mechanism
    Adrenergic receptor agonist

  154. epithelial

    Development asset linked to Disc Medicine in public FDA and regional records.

  155. erythromycin lactobionate

    US regulatory status: approved. Molecular target: Bacterial 70S ribosome.

    Target
    Bacterial 70S ribosome
    Mechanism
    Bacterial 70S ribosome inhibitor

  156. escalation

    Development asset linked to Disc Medicine in public FDA and regional records.

  157. escitalopram

    Development asset linked to Disc Medicine in public FDA and regional records. Mechanism: Serotonin transporter inhibitor.

    Mechanism
    Serotonin transporter inhibitor

  158. escitalopram oxalate

    US regulatory status: approved. Molecular target: Sodium-dependent serotonin transporter.

    Target
    Sodium-dependent serotonin transporter
    Mechanism
    Serotonin transporter inhibitor

  159. esketamine

    Nervous system (N06)

    Nervous system (N06) compound in Disc Medicine's portfolio. Molecular target: Glutamate [NMDA] receptor.

    Target
    Glutamate [NMDA] receptor
    Mechanism
    Glutamate [NMDA] receptor negative allosteric modulator

  160. esmolol

    Development asset linked to Disc Medicine in public FDA and regional records. Mechanism: Beta-1 adrenergic receptor antagonist.

    Mechanism
    Beta-1 adrenergic receptor antagonist

  161. estropipate

    US regulatory status: approved. Molecular target: Estrogen receptor.

    Target
    Estrogen receptor
    Mechanism
    Estrogen receptor alpha agonist

  162. etanercept

    Antineoplastic and immunomodulating agents (L04)

    US regulatory status: approved. Molecular target: Tumor necrosis factor.

    Target
    Tumor necrosis factor
    Mechanism
    TNF-alpha inhibitor

  163. ethinyl estradiol

    US regulatory status: approved. Molecular target: Estrogen receptor.

    Target
    Estrogen receptor
    Mechanism
    Estrogen receptor alpha agonist

  164. etidronate disodium

    US regulatory status: approved. Molecular target: ATP.

    Target
    ATP
    Mechanism
    ATP inhibitor

  165. etomidate

    US regulatory status: approved. Molecular target: GABA-A receptor; anion channel.

    Target
    GABA-A receptor; anion channel
    Mechanism
    GABA-A receptor; anion channel positive modulator

  166. etravirine

    Antiinfectives for systemic use (J05)

    US regulatory status: approved. Molecular target: Human immunodeficiency virus type 1 reverse transcriptase.

    Target
    Human immunodeficiency virus type 1 reverse transcriptase
    Mechanism
    Human immunodeficiency virus type 1 reverse transcriptase inhibitor

  167. everolimus

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Peptidyl-prolyl cis-trans isomerase FKBP1A.

    Target
    Peptidyl-prolyl cis-trans isomerase FKBP1A
    Mechanism
    FK506-binding protein 1A inhibitor

  168. exenatide

    Alimentary tract and metabolism (A10)

    Alimentary tract and metabolism (A10) compound in Disc Medicine's portfolio. Molecular target: Glucagon-like peptide 1 receptor.

    Target
    Glucagon-like peptide 1 receptor
    Mechanism
    Glucagon-like peptide 1 receptor agonist

  169. fapi-

    Development asset linked to Disc Medicine in public FDA and regional records.

  170. fentanyl

    Nervous system (N02)

    US regulatory status: approved. Molecular target: Mu-type opioid receptor.

    Target
    Mu-type opioid receptor
    Mechanism
    Mu opioid receptor agonist

  171. fentanyl citrate

    US regulatory status: approved. Molecular target: Mu-type opioid receptor.

    Target
    Mu-type opioid receptor
    Mechanism
    Mu opioid receptor agonist

  174. filgotinib

    Antineoplastic and immunomodulating agents (L04)

    Antineoplastic and immunomodulating agents (L04) compound in Disc Medicine's portfolio. Molecular target: Tyrosine-protein kinase JAK1.

    Target
    Tyrosine-protein kinase JAK1
    Mechanism
    Tyrosine-protein kinase JAK3 inhibitor

  175. filgotinib maleate

    Development asset linked to Disc Medicine in public FDA and regional records. Molecular target: Tyrosine-protein kinase JAK1.

    Target
    Tyrosine-protein kinase JAK1
    Mechanism
    Tyrosine-protein kinase JAK2 inhibitor

  176. finerenone

    Cardiovascular system (C09)

    US regulatory status: approved. Molecular target: Mineralocorticoid receptor.

    Target
    Mineralocorticoid receptor
    Mechanism
    Mineralocorticoid receptor antagonist

  177. florbetaben (18f)

    Various (V09)

    Various (V09) compound in Disc Medicine's portfolio. Mechanism: Diagnostic agent.

    Mechanism
    Diagnostic agent

  178. fluconazole

    US regulatory status: approved. Molecular target: Lanosterol 14-alpha demethylase.

    Target
    Lanosterol 14-alpha demethylase
    Mechanism
    Cytochrome P450 51 inhibitor

  179. fludeoxyglucose f-18

    US regulatory status: approved. Mechanism: Diagnostic agent.

    Mechanism
    Diagnostic agent

  180. fluocinolone acetonide

    US regulatory status: approved. Molecular target: Glucocorticoid receptor.

    Target
    Glucocorticoid receptor
    Mechanism
    Glucocorticoid receptor agonist

  181. fluorouracil

    US regulatory status: approved. Molecular target: DNA.

    Target
    DNA
    Mechanism
    Thymidylate synthase inhibitor

  182. fluoxetine hydrochloride

    US regulatory status: approved. Molecular target: Sodium-dependent serotonin transporter.

    Target
    Sodium-dependent serotonin transporter
    Mechanism
    Serotonin transporter inhibitor

  183. fluphenazine decanoate

    US regulatory status: approved. Molecular target: D(2) dopamine receptor.

    Target
    D(2) dopamine receptor
    Mechanism
    Dopamine D2 receptor antagonist

  184. fluticasone

    Development asset linked to Disc Medicine in public FDA and regional records.

  185. fluvoxamine

    Development asset linked to Disc Medicine in public FDA and regional records. Mechanism: Serotonin transporter inhibitor.

    Mechanism
    Serotonin transporter inhibitor

  186. fluvoxamine maleate

    US regulatory status: approved. Molecular target: Sodium-dependent serotonin transporter.

    Target
    Sodium-dependent serotonin transporter
    Mechanism
    Serotonin transporter inhibitor

  187. folate

    Development asset linked to Disc Medicine in public FDA and regional records.

  188. fosamprenavir

    Antiinfectives for systemic use (J05)

    Antiinfectives for systemic use (J05) compound in Disc Medicine's portfolio.

  189. gadoterate meglumine

    US regulatory status: approved. Mechanism: Diagnostic agent.

    Mechanism
    Diagnostic agent

  193. gemcitabine

    US regulatory status: approved. Mechanism: DNA polymerase (alpha/delta/epsilon) inhibitor.

    Mechanism
    DNA polymerase (alpha/delta/epsilon) inhibitor

  194. gemfibrozil

    US regulatory status: approved. Molecular target: Peroxisome proliferator-activated receptor alpha.

    Target
    Peroxisome proliferator-activated receptor alpha
    Mechanism
    Peroxisome proliferator-activated receptor alpha agonist

  195. glucagon hydrochloride

    US regulatory status: approved. Molecular target: Glucagon receptor.

    Target
    Glucagon receptor
    Mechanism
    Glucagon receptor agonist

  196. golimumab

    Antineoplastic and immunomodulating agents (L04)

    US regulatory status: approved. Molecular target: Tumor necrosis factor.

    Target
    Tumor necrosis factor
    Mechanism
    TNF-alpha inhibitor

  197. gozetotide

    Various (V09)

    Various (V09) compound in Disc Medicine's portfolio. Mechanism: Diagnostic agent.

    Mechanism
    Diagnostic agent

  198. granule

    Development asset linked to Disc Medicine in public FDA and regional records.

  199. granules

    Development asset linked to Disc Medicine in public FDA and regional records.

  200. haloperidol

    US regulatory status: approved. Molecular target: D2-like dopamine receptor.

    Target
    D2-like dopamine receptor
    Mechanism
    Serotonin 2a (5-HT2a) receptor antagonist

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.